TRPV1 Agonist Composition for Enhanced Nutrient Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
TRPV1 agonists like capsaicin, while effective in enhancing bioavailability, cause undesirable side effects such as increased bleeding risk and reduced oral drug bioavailability, and reduced intestinal absorption of glucose.
Innovation Solution
Combining herbs with TRPV1 agonists such as capsaicin, piperine, 6-gingerol, and sanshool in specific Scoville Heat Unit (SHU) ranges to provide a therapeutic dose while minimizing side effects, including using Zingiber officinale, Piper nigrum, Capsicum annuum, and Zanthoxylum piperitum to create a composition that activates TRPV1 receptors effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRPV1 agonists like capsaicin are used to enhance nutrient absorption, then bioavailability is improved, but side effects such as increased bleeding risk and reduced intestinal absorption of glucose occur
Solution Approach 1:
The patent combines multiple TRPV1 agonists (capsaicin, piperine, 6-gingerol, sanshool) from different herb sources into a composite composition. This composite approach provides synergistic enhancement of nutrient bioavailability while distributing and mitigating the harmful side effects through the combined action of multiple milder agonists rather than relying on high doses of a single potent agonist like capsaicin
2Reliability
If high doses of TRPV1 agonists are administered to achieve therapeutic effect, then TRPV1 receptor activation is enhanced, but undesirable side effects increase
Solution Approach 1:
The patent merges multiple TRPV1 agonists from different herbal sources into a single composition. The combined agonists (capsaicin from Capsicum annuum, piperine from Piper nigrum, 6-gingerol from Zingiber officinale, and sanshool from Zanthoxylum piperitum) work synergistically to achieve effective TRPV1 activation at lower individual doses, thereby reducing the harmful side effects associated with high doses of single agonists
Solution Approach 2:
The patent changes the parameter composition from a single high-dose agonist to a multi-component formulation with specific Scoville Heat Unit (SHU) ranges. This parameter transformation allows achieving the same therapeutic effect through distributed, lower-dose multiple agonists, which reduces the intensity of harmful side effects while maintaining efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination enhances nutrient absorption and bioavailability while mitigating side effects, as demonstrated by increased plasma levels and prolonged residence times of theophylline and significant absorption of nutrients, with improved digestive enzyme secretion and reduced discomfort.
Implementation Method 1
The TRPV1 receptors are activated by both by heat greater than 43° Celsius and TRPV1 agonists including vanilloids such as capsaicin... When TRPV1 receptors are activated by TRPV1 agonists, blood flow to the area of the TRPV1 receptor is increased, increasing capillary action in the walls of the gastrointestinal tract, and resulting in increased digestion and absorption of nutrients.
Implementation Method 2
Concomitant absorption of capsicum increased levels of theophylline from 86.06+/−9.78 mg H/liter to 138.32+/−17.27 mg H/liter... Peak theophylline plasma levels increased from 6.65+/−0.76 to 8.78+/−0.98 mg/liter, and mean residence times of theophylline increased from 14.94+/−2.97 to 20.98+/−5.75 H
Data Source
AI summary
For enhancing bioavailability, a composition is administered comprising a Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) agonist with a combined Scoville Heat Unit (SHU) milligram (mg) dose in the range of 280,000 to 400,000 SHU mg.